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Porphyrias are a group of metabolic diseases that arise from deficiencies in the heme biosynthetic pathway. A partial deficiency
in hydroxymethylbilane synthase (HMBS) produces a hepatic disorder named Acute Intermittent Porphyria (AIP); the acute
porphyria is more frequent in Argentina. In this paper we review the results obtained for 101 Argentinean AIP families and 6
AIP families from foreign neighbour countries studied at molecular level at Centro de Investigaciones sobre Porfirinas y Porfirias
(CIPYP). Thirty-five different mutations were found, of which 14 were described for the first time in our population. The most
prevalent type of mutations was the missense mutations (43%) followed by splice defects (26%) and small deletions (20%). An odd
case of a double heterozygous presentation of AIP in a foreign family from Paraguay is discussed. Moreover, it can be noted that 38
new families were found carrying the most frequent mutation in Argentina (p.G111R), increasing to 55.66% the prevalence of this
genetic change in our population and adding further support to our previous hypothesis of a founder effect for this mutation in
Argentina. Identification of patients with an overt AIP is important because treatment depends on an accurate diagnosis, but more
critical is the identification of asymptomatic relatives to avoid acute attacks which may progress to death.
1. Introduction
The porphyrias are a heterogeneous group of metabolic
disorders that result from the decreased activity of a specific
enzyme of the heme pathway and are characterized by the
overproduction and excretion of heme intermediates in urine
and/or stool and their accumulation in certain tissues [1–3].
Acute Intermittent Porphyria (AIP, OMIM 176000) is
the most common of the acute hepatic porphyrias. It is an
autosomal dominant disorder caused by a deficient activ-
ity of hydroxymethylbilane synthase (HMBS, EC 4.3.1.8),
also referred to as porphobilinogen deaminase, producing
a markedly increase in the urinary excretion of ALA and
PBG. The symptoms may frequently appear at any time
after puberty and are characterized by acute neurovisceral
signs which include intermittent attacks of abdominal pain,
constipation, vomiting, hypertension, tachycardia, fever, and
various peripheral and central nervous system manifesta-
tions. Acute attacks may frequently result from exposure to
diverse porphyrinogenic drugs, alcohol ingestion, reduced
calories intake due to fasting or dieting, infections, and
hormones which stimulate heme synthesis by ALA-synthase
induction, thereby increasing the production of the por-
phyrin precursors ALA and PBG [4, 5].
HMBS is the third enzyme involved in heme pathway and
catalyzes the head to tail condensation of four molecules of
PBG to form the lineal tetrapyrrole HMB. It is encoded by a
single gene localized at the chromosomal region 11q23.3. The
cDNA and the entire 10 kb gene have been sequenced includ-
ing the 5󸀠 regulatory, 3󸀠 regulatory, and intronic regions. The
gene contains 15 exons and 2 distinct promoters that gen-
erate housekeeping and erythroid transcripts by alternative
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splicing and cDNAs encoding the 44-kD housekeeping and
the 42-kD erythroid-specific isoenzymes, which have been
isolated and characterized [6].
AIP is the most common acute porphyria in our country
[7]. It is an autosomal dominant disorder with incomplete
penetrance although some cases of homozygosity or double
heterozygosity have been described, in most cases associated
with childhood and more severe manifestations [8–21]. The
identification of asymptomatic heterozygotes in families with
affected individuals is essential for their counselling to avoid
specific precipitating factors, but as the enzyme assay is only
about 80% accurate [1], the use of molecular techniques to
identify specific mutations in the HMBS gene is essential for
accurate diagnosis of affected members in AIP families [7].
To date about 390 different mutations have been identi-
fied in the HMBS gene causing AIP (Human Gene Mutation
Database HGMD, http://www.hgmd.cf.ac.uk/ac/index.php);
most of them were either private or found in a few unrelated
families, showing the molecular heterogeneity of AIP.
We review here all the mutations found in 101 Argen-
tinean and 6 foreign AIP families and studied during the
last 20 years at CIPYP. Four new mutations and 31 already
described genetic changes were found; some of them were
detected for the first time in our population. It must be high-
lighted that 59 unrelated families carry the same mutation,
p.G111R (55.66%), increasing its number with respect to that
previously found [22], suggesting a founder effect for this
genetic change as has been described for different mutations
in other populations [23–25].
2. Materials and Methods
2.1. Patients. Informed consent was obtained from all
patients following the standards of UNESCO Declarations-
DD.HH Genome and Genetic Data (http://www.unesco.org/
shs/ethics), Declaration of Helsinki was taken into consid-
eration, and the study was approved by the Institutional
Research Ethics Committee of the CIPYP, National Scientific
and Technical Research Council (CONICET), University of
Buenos Aires (UBA).
FromMarch 1994 to July 2014, 106 unrelated Argentinean
families were studied at biochemical and molecular level. All
patients had current symptoms of AIP and the diagnosis was
made on the basis of their clinical history of at least one acute
attack associated with increased excretion of ALA and PBG
in urine and reduced HMBS activity in red blood cells [1].
The final diagnosis of the patients was established by genetic
studies. Unrelatedness was determined by family inquiries.
2.2. Identification of Mutations
2.2.1. DNA Isolation and HMBS Amplification. Genomic
DNAwas extracted from peripheral blood collected in EDTA
using the commercial kit illustraTM blood genomicPrepMini
Spin Kit (GEHealthcare).Mutational analysis was performed
amplifying the promoters, all exons, and the intron/exon
boundaries of the HMBS gene by PCR using the specific
primers shown in Table 1. Promoter regions and genomic
sequence from exon 3 to noncoding exon 15 were amplified
in only two fragments using Platinum Taq DNA Polymerase
High Fidelity enzyme (Invitrogen by Life Technologies).
Alternatively, exons 3 to 15 and their flanking intron regions
were amplified in 5 fragments as indicated (see Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2015/946387), employing recombinant Taq DNA Polymerase
(Invitrogen by Life Technologies).
2.2.2. RT PCR. RNA was isolated from the leukocytes using
the commercial kit Ribo Pure–Blood (Ambion) and reverse
transcribed with M-MLV Reverse Transcriptase and Oligo
(dT)
12–18 primers (Invitrogen), according to manufacturer’s
instructions. The HMBS cDNA was amplified with the
primers Fc (5󸀠 aaagcctgtttaccaaggagc 3󸀠)–Rc (5󸀠 caccaccagctc-
caagatgt 3󸀠).
All PCR products were checked in 1.5% agarose gel.
2.2.3. Sequencing Analysis. The amplified products were
purified with the Bioneer Accuprep PCR Purification Kit
(Bioneer) or QIAquick PCR/Gel Purification Kit (QIAGEN)
and were automatically sequenced by Macrogen (Macrogen
Inc., Gangseo-gu, Seoul, Korea, ABI3730XL, Macrogen). The
sequencing primers are listed in Supplementary Material.
All mutations were confirmed by sequencing both DNA
strands of at least two different PCR products. To validate the
new mutations, their absence in 50 control individuals has
been performed. Nucleotides were numbered according to
the cDNA sequence for the housekeeping isoform of HMBS
transcript variant 1 (GenBank Accession NM 000190.3) in
which the A of the ATG initiation codon was numbered as
1.
2.2.4. Databases. The Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk/) was used for information about
reported mutations in the HMBS gene.
3. Results
At present 177 AIP families (299 affected individuals) were
diagnosed at CIPYP. Of them, 107 were also studied at
molecular level and results for 48 families were already
described [7, 28, 29, 34]. In the last 10 years 58 new families
were also biochemically diagnosed as AIP and molecular
analysis revealed 19 mutations, 4 new and 15 already reported
of which 7 were described for the first time in our population
(Table 1).
From the novel mutations, two were splice site mutations
at acceptor splice sites. One was an A to G transition in the
penultimate base of intron 8 leading to the in-frame deletion
of 15 bp with the loss of the first 5 amino acids of exon 9
(c.423-2A>G) by the use of a cryptic site (Figure 1).The other
was also an A to G transition in the last base of intron 14
(c.913-1G>A) predicting the skipping of exon 15.
In another family, an out of frame new duplication of 7 bp
in exon 7 which generates a stop codon 17 bp upstream (c.
301 307dupCCCACTG) was found (Figure 2).
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Table 2: Biochemical data and mutation status of the family from Paraguay.
Patient Age ALAmg/24 h
PBG
mg/24 h
Porph.
𝜇g/24 h
PPI𝜆:
619 nm HMBS activity Mutation status
Proband 38 2.7 8.7 188 1.80 44.72 c.772-1 G>A
Mother 67 — — — 1.85 46.24 c.772-1 G>A
Husband 62 — — — 1.00 61.20 p.R321H
Daughter 23 6.6 32.5 589 1.23 58.06 c.772-1 G>A/p.R321H
Daughter 26 6.1 24.7 782 1.29 31.75 c.772-1 G>A/p.R321H
Daughter 30 1.0 1.2 37 1.00 44.77 p.R321H
Age in years at diagnosis. Porph.: porphyrins.
Normal values: ALA:≤4mg/24 h: PBG:≤2mg/24 h; porphyrins: 2–250𝜇g/24 h; Plasma Porphyrin Index (PPI)≤1.30 (𝜆: 619); HMBS activity: 84.51± 11.96U/ml
GR (F); 73.13 ± 13.62U/ml GR (M).
TGCCAGAGAAGAGCTCCCTGCGAACAGCATCCCAGCTGCAAAG
Exon 8 Exon 9 Exon 9–15bp
15bp
Figure 1: Electropherogram showing c.423-2A>G mutation RT-
PCR product.
In another two families, 2 bands were found whenHMBS
gene was amplified, one of the expected size and another of
300 bp (Figure 3(a)). The sequencing of the small purified
band revealed a large deletion of 5228 bp spanning from
intron 2 to noncoding exon 15 (Figures 3(c) and 3(d)).
The other 15 mutations were previously described point-
ing that 7 of them were identified for the first time in our
population (Table 1).
Of note are the results obtained for a foreign family from
Paraguay. Two female symptomatic members carried two
already described mutations. One was a splice site mutation
in the last base of intron 12 inherited from the mother (c.772-
1G>A) which leads to exon 13 skipping [39]. The other was
a point mutation (c.962G>A) in exon 15 which produces an
amino acid change (p.R321H) and was inherited from the
father [22]. Another asymptomatic sister carried only this last
mutation. The biochemical values and molecular results for
this family are shown in Table 2.
In addition, 38 new families carry the p.G111R mutation
previously described for another 21 unrelated families [7]
ascending the number of unrelated Argentinean families that
carry this mutation to 59 (55.66%) adding further support to
our previous hypothesis of a founder effect [28].
4. Discussion
During the last 20 years, 35 different mutations were found:
14 described in Argentina for the first time and 21 already
reported for other populations. These 35 genetic changes
include 15 missense mutations, 9 splice defects, 7 small dele-
tions, 2 small insertions, one gross deletion, and 1duplication.
One of the splice site mutations is located in the −2
position of the acceptor splice site of intron 8 (c.423-2A>G,
GENBANK HM856802) leading to the in-frame deletion of
15 bp (Figure 1). The same result has been found for a point
mutation in the last base of intron 8 already described for
another Argentinean family [34].
The other novel splice site mutation was an A to G
transition in the last base of intron 14 (c.913-1G>A). Although
no sample was available to carry out RT-PCR studies, as this
base is 100% conserved in the consensus splice site, it is very
likely that this substitution leads to exon 15 skipping as it has
been described by Puy et al. for a different mutation affecting
the same acceptor splice site [39].
The novel frameshift mutation (Figure 2), c.301 307dup-
CCCACTG (GENBANK HQ7315521), introduces a prema-
ture stop codon at exon 8 so the transcript codified by this
allele is most likely to be degraded by the nonsense-mediated
mRNA decay (NMD) [42]. This mutation has been found in
two unrelated Argentinean families (Table 1).
In two families, two bandswere foundwhen PCRproduct
was run in an agarose gel, one of the expected size and
another of 300 bp (Figure 3(a)). When these were sequenced
the large one did not show any genetic change but it showed
an apparent homozygosis of the 6 variable SNPs in the studied
population (g.3119T>G, g.3581A>G, g.3982T>C, g.6479T>G,
g.7064C>A, g.7539C>T) Cerbino [43]. However, as it is
shown in Figure 3(b), for two of these SNPs, (g.6479T>G
and g.7539C>T), the proband and her sister carry the same
allelic variant (6479 G and 7539 C), but the symptomatic
daughter of one of them carries another allelic variant (6479
T and 7539 T) inherited from her father. The analysis of
the smaller band indicated that this corresponded to the
other allele with a large deletion of 5228 bp spanning from
intron 2 to noncoding exon 15. As indicated in Figures 3(c)
and 3(d), positions g.3078 g.3081 and g.8306 g.8309 shared
the same region (CCCC) so it was impossible to determine
the breakpoint of the deletion. Only another gross deletion
of 4620 bp but including promoter and exon 1 has been
described by Di Pierro et al. [44].
In the family from Paraguay two double heterozygotes
relatives were found. The proband of this family has been
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GAAGGACCTGCCCA
TCCTTGAAGGACCTGCCCACTGTGCTTCCTCCTGGCT
(a)
GAAGGACCTGCCCACTG
TGCTTCCTCCTGGCTTCACCATCGGAGCCATCTGCAAG
CCCACTGTGCTTCCTCCTGGCTTCACCATCGGAGCCAT
TTGAAGGACCTGCCCACTGTGCTTCCTCCTGGCTTCTGCATCCGAGCCATCAGCCATTTACAATCTTGAAAC
Control sequence
Mutated sequence
(b)
Figure 2: Electropherograms showing (a) control sequence; (b) c.301 307dupCCCACTG mutation; the duplicated sequence is underlined.
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electropherogram of the 300 bp band showing the shared region between intron 2 and noncodifying exon 15; (d) scheme showing the deleted
region.
6 BioMed Research International
diagnosed as AIP 15 years ago carrying one reported muta-
tion, c.772-1G>A, a splice site mutation which leads to exon
13 skipping [39]. When three of her daughters came for
diagnosis, it was found that one of them, asymptomatic but
with aHMBS activity reduced to 50%of control value, did not
carry the family mutation. A reexamination of mother DNA
confirmed only the previous mutation but a more extensive
study of her daughters indicated that two of them carry two
mutations, the maternal mutation and another previously
described missense mutation, p.R321H [22], inherited from
their father. The asymptomatic daughter carries this last
genetic change. It is interesting to note that these patients
developed the symptomatology recently (23 and 26 years
old) and only one of them occasionally suffered from some
abdominal pain. In most of homozygous or double heterozy-
gous AIP reported cases the enzyme activity was severely
reduced and the symptomatology was developed at an early
age with severe neurological manifestations [13, 15, 16, 18–21].
In several of these cases essential arginine residues for enzyme
activity are affected [45–47]. In these new cases themutations
found do not seem to be essential for enzyme expression or
activity. This is likely true for the missense mutation which
affects a nonconserved arginine residue in exon 15 located
in the 29-residue insert between strands 𝛽3 and 𝛼2 in the
domain 3 only present in the human enzyme sequence [47].
However, the splice site mutation leads to exon 13 skipping
[39], an exon where the residue Cys261 is located to which
the essential DPM (dipyrromethane) cofactor is bound [47].
Nevertheless this combined heterozygous genotype does not
seem to have amore serious impact onHMBS activity than in
the heterozygous form, since the activity of the three sisters
is approximately the same. These results highlighted the
importance of carrying out a complete genotype investigation
of family members of a known carrier.
Finally 38 new families carrying the frequent p.G111R
mutation have been characterized leading to 59 (55.66%)
the number of Argentinean families carrying this genetic
change. The other mutations were found in one or in a
few families. Efforts were made to know if the AIP patients
showing this mutation have a common ancestral origin.
Detailed pedigrees were unavailable, because either relatives
of many of the patients were dead or the relatives themselves
had limited knowledge of their families ancestry. Since the
p.G111R mutation occurs at a hot spot CpG dinucleotide, it
can be possible that the mutation had been originated several
times independently. However, a preliminary analysis of four
intragenic and four flanking DNA polymorphic markers
indicated that all tested patients with p.G111Rmutation (7/21)
had at least one common allele for all intragenic and flanking
markers. Argentinean AIP patients with other mutations
had different alleles for the markers [28]. These previous
results had suggested that individuals carrying this mutation
were most likely related. Extended haplotype analysis on a
large group of families with the p.G111R mutation and their
relatives add further evidence to our previous hypothesis
about a founder effect for this mutation in the Argentinean
population [43]. Microsatellite studies in these families are
being carried out.
5. Conclusions
This study emphasizes the molecular heterogeneity of AIP
and the importance of molecular techniques as the most
appropriate tools for detecting and identifying specific muta-
tions in carriers of affected families to avoid the contact with
precipitating agents.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
Gabriela Nora Cerbino is a postgraduate student from the
University of Buenos Aires. Alcira Batlle, Mar´ıa Victoria
Rossetti, Victoria Estela Parera, and Esther Noemı´ Gerez
are Superior, Independent, and Associated Researchers from
CONICET. Viviana Alicia Melito and Laura Sabina Varela
are Principal and Associated Members at the Technical
Career from CONICET. The authors would like to thank
H. Muramatsu, MD, Dr. MN Guolo, Lic. LM Oliveri, and
Mrs. VI Castillo for their technical assistance. This work was
supported by Grants X253 (2004–2007), X304 (2004–2007),
EX195 (2008–2010), EX165 (2008–2010), and W542 (2011–
2014) from UBA, PICT 0268 (2009–2012) from ANPCYT,
and PIP 049 (2012–2014) from CONICET.
References
[1] A. M. C. Batlle, “Porfirias y Porfirinas. Aspectos cl´ınicos,
bioquı´micos y biologı´a molecular,” Acta Bioquı´mica Cl´ınica
Latinoamericana. Serie: Actualizaciones Me´dico-Bioquı´micas,
supplement 3, pp. 145–171, 1997.
[2] A. Pietrangelo, “Theporphyrias: pathophysiology,” Internal and
Emergency Medicine, supplement 1, pp. S65–S71, 2010.
[3] H. Puy, L. Gouya, and J.-C. Deybach, “Porphyrias,”The Lancet,
vol. 375, no. 9718, pp. 924–937, 2010.
[4] K. E. Anderson, S. Sassa, D. F. Bishop, and R. J. Desnick, “Dis-
orders of heme biosynthesis: X-linked sideroblasticanemia and
the porphyrias,” in The Metabolic and Molecular Basis of
Inherited Disease, C. R. Scriver, A. L. Beaudet, D. Valle, and W.
S. Sly, Eds., vol. 2, pp. 2991–3062, McGraw-Hill, New York, NY,
USA, 2001.
[5] R. Kauppinen, “Porphyrias,” The Lancet, vol. 365, no. 9455, pp.
241–252, 2005.
[6] R. J. Desnick, M. Balwani, and K. E. Anderson, “Inherited
Porphyrias,” in Emery and Rimoin’s Principles and Practice of
Medical Genetics, D. L. Rimoin, R. E. Pyeritz, and B. Korf, Eds.,
chapter 99, pp. 1–32, Elsevier, SanDiego, Calif, USA, 6th edition,
2013.
[7] V. E. Parera, A. de Siervi, L. Varela, M. V. Rossetti, and A. M.
D. C. Batlle, “Acute porphyrias in the Argentinean population:
a review,”Cellular andMolecular Biology, vol. 49, no. 4, pp. 493–
500, 2003.
[8] C. Picat, M. H. Delfau, F. W. M. de Rooij et al., “Identification
of the mutations in the parents of a patient with a putative
compound heterozygosity for acute intermittent porphyria,”
BioMed Research International 7
Journal of Inherited Metabolic Disease, vol. 13, no. 5, pp. 684–
686, 1990.
[9] G. J. J. Beukeveld, B. G. Wolthers, Y. Nordmann, J. C. Deybach,
B. Grandchamp, and S. K. Wadman, “A retrospective study of a
patient with homozygous formof acute intermittent porphyria,”
Journal of InheritedMetabolic Disease, vol. 13, no. 5, pp. 673–683,
1990.
[10] D. H. Llewellyn, S. J. Smyth, G. H. Elder, A. C. Hutchesson, J. M.
Rattenbury, and M. F. Smith, “Homozygous acute intermittent
porphyria: compound heterozygosity for adjacent base tran-
sitions in the same codon of the porphobilinogen deaminase
gene,” Human Genetics, vol. 89, no. 1, pp. 97–98, 1992.
[11] R. J. Hift, P. N. Meissner, G. Todd et al., “Homozygous variegate
porphyria: an evolving clinical syndrome,” Postgraduate Medi-
cal Journal, vol. 69, no. 816, pp. 781–786, 1993.
[12] A. Edixhoven-Bosdijk, F. W. de Rooij, E. de Baar-Heesakkers,
and J. H. Wilson, “Residual activity of human porphobilinogen
deaminase with R167Q or R167W mutations: an explanation
for survival of homozygous and compound heterozygous acute
intermittent porphyrics,” Cellular and Molecular Biology, vol.
48, no. 8, pp. 861–866, 2002.
[13] C. Solis, A. Martinez-Bermejo, T. P. Naidich et al., “Acute inter-
mittent porphyria: studies of the severe homozygous dominant
disease provides insights into the neurologic attacks in acute
porphyrias,”Archives of Neurology, vol. 61, no. 11, pp. 1764–1770,
2004.
[14] J. Hessels, G. Voortman, A. van der Wagen, C. van der
Elzen, H. Scheffer, and F. M. J. Zuijderhoudt, “Homozygous
acute intermittent porphyria in a 7-years-old boy with massive
excretions of porphyrins and porphyrin precursors,” Journal of
Inherited Metabolic Disease, vol. 27, no. 1, pp. 19–27, 2004.
[15] L. Sheppard and T. Dorman, “Anesthesia in a child with
homozygous porphobilinogen deaminase deficiency: a severe
form of acute intermittent porphyria,” Paediatric Anaesthesia,
vol. 15, no. 5, pp. 426–428, 2005.
[16] E. McGovern, P. Fleming, and A. O’Marcaigh, “The dental
management of five paediatric patients with a history of
acute intermittent porphyria,” European Archives of Paediatric
Dentistry, vol. 8, no. 4, pp. 215–218, 2007.
[17] V. A.Melito,M. V. Rossetti, V. E. Parera, and A. Batlle, “Porfirias
poco frecuentes. Casos detectados en la poblacio´n argentina,”
Revista Argentina de Dermatologı´a, vol. 87, pp. 248–263, 2006.
[18] A. Dibi, H. Aitouamar, and A. Bentahila, “Recurrent flaccid
paralysis indicative of acute intermittent porphyria in a child,”
Archives de Pe´diatrie, vol. 17, no. 12, pp. 1670–1672, 2010.
[19] J. I. Bhat, U. A. Qureeshi, and M. A. Bhat, “Acute intermittent
porphyria with transient cortical blindness,” Indian Pediatrics,
vol. 47, no. 11, pp. 977–978, 2010.
[20] E. Anyaegbu, M. Goodman, S.-Y. Ahn, M. Thangarajh, M.
Wong, and M. Shinawi, “Acute intermittent porphyria: a diag-
nostic challenge,” Journal of Child Neurology, vol. 27, no. 7, pp.
917–921, 2012.
[21] B. Zhao, Q. Wei, Y. Wang, Y. Chen, and H. Shang, “Posterior
reversible encephalopathy syndrome in acute intermittent por-
phyria,” Pediatric Neurology, vol. 51, no. 3, pp. 457–460, 2014.
[22] M. M. Schuurmans, X. Schneider-Yin, U. B. Ru¨fenacht et al.,
“Influence of age and gender on the clinical expression of
acute intermittent porphyria based on molecular study of por-
phobilinogen deaminase gene among Swiss patient,”Molecular
Medicine, vol. 7, no. 8, pp. 535–542, 2001.
[23] J.-S. Lee and M. Anvret, “Identification of the most com-
mon mutation within the porphobilinogen deaminase gene in
Swedish patients with acute intermittent porphyria,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 88, no. 23, pp. 10912–10915, 1991.
[24] X.-F. Gu, F. de Rooij, J. S. Lee et al., “High prevalence of a point
mutation in the porphobilinogen deaminase gene in Dutch
patients with acute intermittent porphyria,” Human Genetics,
vol. 91, no. 2, pp. 128–130, 1993.
[25] X. Schneider-Yin, M. Hergersberg, D. E. Goldgar et al.,
“Ancestral founder of mutationW283X in the porphobilinogen
deaminase gene among acute intermittent porphyria patients,”
Human Heredity, vol. 54, no. 2, pp. 69–81, 2002.
[26] R. Kauppinen, S. Mustajoki, H. Pihlaja, L. Peltonen, and P.Mus-
tajoki, “Acute intermittent porphyria in Finland: 19 mutations
in the porphobilinogen deaminase gene,” Human Molecular
Genetics, vol. 4, no. 2, pp. 215–222, 1995.
[27] G. Lundin, J. Hashemi, Y. Floderus et al., “Four mutations in
the porphobilinogen deaminase gene in patients with acute
intermittent porphyria,” Journal of Medical Genetics, vol. 32, no.
12, pp. 979–981, 1995.
[28] A. de Siervi,M. V. Rossetti, V. E. Parera et al., “Identification and
characterization of hydroxymethylbilane synthase mutations
causing acute intermittent porphyria: evidence for an ancestral
founder of the common G111R mutation,” American Journal of
Medical Genetics, vol. 86, no. 4, pp. 366–375, 1999.
[29] A. de Siervi, D. E. W. Ca´diz, V. E. Parera, A. M. D. C. Batlle, and
M. V. Rossetti, “Identification and characterization of two novel
mutations that produce acute intermittent porphyria: a 3-base
deletion (841-843delGGA) and a missense mutation (T35M),”
Human Mutation, vol. 16, no. 4, p. 373, 2000.
[30] A. Gregor, X. Schneider-Yin, U. Szlendak et al., “Molecu-
lar study of the hydroxymethylbilane synthase gene (HMBS)
among Polish patients with acute intermittent porphyria,”
Human Mutation, vol. 19, no. 3, p. 310, 2002.
[31] Y. A. Luchinina, V. L. Surin, A. V. Luk’yanenko, I. V. Karpova,
Y. S. Pustovoit, and S. K. Kravchenko, “Molecular diagnostics
of acute intermittent porphyria in Russia,” European Journal of
HumanGenetics, vol. 13, supplement 1, p. 134, 2005, Proceedings
of the European Society of Human Genetics International
Conference.
[32] X.-F. Gu, F. de Rooij, E. de Baar et al., “Two novel mutations
of the porphobilinogen deaminase gene in acute intermittent
porphyria,” Human Molecular Genetics, vol. 2, no. 10, pp. 1735–
1736, 1993.
[33] M. D. Cappellini, F. M. di Montemuros, E. di Pierro, and G.
Fiorelli, “Hematologically important mutations: acute intermit-
tent porphyria,” Blood Cells, Molecules, and Diseases, vol. 28, no.
1, pp. 5–12, 2002.
[34] A. de Siervi,M.Me´ndez, V. E. Parera, L. Varela, A.M. Batlle, and
M. V. Rossetti, “Acute intermittent porphyria: characterization
of two novelmutations in the porphobilinogen deaminase gene,
one amino acid deletion (453-455delAGC) and one splicing
aceptor site mutation (IVS8-1G>T),” Human Mutation, vol. 14,
no. 4, article 355, 1999.
[35] M. H. Delfau, C. Picat, F. de Rooij et al., “Molecular hetero-
geneity of acute intermittent porphyria: identification of four
additional mutations resulting in the CRIM-negative subtype
of the disease,” The American Journal of Human Genetics, vol.
49, no. 2, pp. 421–428, 1991.
[36] M. H. Delfau, C. Picat, F. W. M. de Rooij et al., “Two different
pointG toAmutations in exon 10 of the porphobilinogendeam-
inase gene are responsible for acute intermittent porphyria,”The
Journal of Clinical Investigation, vol. 86, no. 5, pp. 1511–1516, 1990.
8 BioMed Research International
[37] C. S. Mgone, W. G. Lanyon, M. R. Moore, G. V. Louie, and
J. M. Connor, “Identification of five novel mutations in the
porphobilinogen deaminase gene,” Human Molecular Genetics,
vol. 3, no. 5, pp. 809–811, 1994.
[38] C.-H. Chen, K. H. Astrin, G. Lee, K. E. Anderson, and R.
J. Desnick, “Acute intermittent porphyria: identification and
expression of exonic mutations in the hydroxymethylbilane
synthase gene. An initiation codon missense mutation in
the housekeeping transcript causes “variant acute intermittent
porphyria” with normal expression of the erythroid-specific
enzyme,”The Journal of Clinical Investigation, vol. 94, no. 5, pp.
1927–1937, 1994.
[39] H. Puy, J. C.Deybach, J. Lamoril et al., “Molecular epidemiology
and diagnosis of PBG deaminase gene defects in acute intermit-
tent porphyria,” The American Journal of Human Genetics, vol.
60, no. 6, pp. 1373–1383, 1997.
[40] Y. Floderus, P. M. Shoolingin-Jordan, and P. Harper, “Acute
intermittent porphyria in Sweden. Molecular, functional and
clinical consequences of some new mutations found in the
porphobilinogen deaminase gene,”Clinical Genetics, vol. 62, no.
4, pp. 288–297, 2002.
[41] H. Puy, J. C. Deybach, J. Lamoril, A. M. Robreau, and Y.
Nordmann, “Detection of four novel mutations in the porpho-
bilinogen deaminase gene in French Caucasian patients with
acute intermittent porphyria,” Human Heredity, vol. 46, no. 3,
pp. 177–180, 1996.
[42] L. E. Maquat, “Nonsense-mediated mRNA decay: splicing,
translation and mRNP dynamics,” Nature Reviews Molecular
Cell Biology, vol. 5, no. 2, pp. 89–99, 2004.
[43] G. N. Cerbino,High prevalence of p.G111R mutation in Argentine
patients with acute intermittent Porphyria. Newmutations found
in PBGD gene [Pre Graduate thesis], 2011.
[44] E. Di Pierro, V. Brancaleoni, F. Stanzial, F. Benedicenti, C.
Castellan, and M. D. Cappellini, “Novel human pathological
mutations. Gene symbol: HMBS. Disease: porphyria, acute
intermittent,” Human Genetics, vol. 126, no. 2, p. 339, 2009.
[45] P. D. Brownlie, R. Lambert, G. V. Louie et al., “The three-
dimensional structures of mutants of porphobilinogen deam-
inase: toward an understanding of the structural basis of acute
intermittent porphyria,” Protein Science, vol. 3, no. 10, pp. 1644–
1650, 1994.
[46] G. Song, Y. Li, C. Cheng et al., “Structural insight into acute
intermittent porphyria,” The FASEB Journal, vol. 23, no. 2, pp.
396–404, 2009.
[47] R. Gill, S. E. Kolstoe, F. Mohammed et al., “Structure of human
porphobilinogen deaminase at 2.8 A˚: the molecular basis of
acute intermittent porphyria,” Biochemical Journal, vol. 420, no.
1, pp. 17–25, 2009.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
